EpiNeuron®

ALIAmides – autacoid local injury antagonist amides

The term autacoids refers to endogenous compounds or their precursors or other derivatives produced on demand, and then metabolised in the same cells and/or tissues.

ALIAmides represent a group of endogenous bioactive lipids, including palmitoylethanolamide (PEA), oleoylethanolamide (OEA), and stearoylethanolamide (SEA), which play a central role in a number of biological processes, including pain, inflammation, and lipid metabolism.

Classical medications block only one target receptor, which leads to a sudden cessation of the physiological process, but also leads to their side effects.

 

Modern medicine deals with endogenous compounds or their derivatives that use physiological pathways for modifying pathological processes, so the likelihood of side effects is low.

Palmitoylethanolamide (PEA)

Endogenous lipid mediator which, during neuroinflammatory and neurodegenerative diseases, presents a factor of protection against inflammation, pain, and neuronal damage.

The mechanism of action:

• Regulation of mast cell and microglia activity  (antagonist of proinflammatory factors)
• Directly through PPAR-alpha and GPR55 receptors  (neuroprotective properties)
• Indirect activation of cannabinoid receptors, CB1 and CB2, and TRPV1 ion channels (inflammation and pain regulation)

Owing to the synergism of the multiple mechanism of action, PEA achieves significant therapeutic effects on the CNS and PNS!

Oxidative stress

Free radicals (oxidants) are molecules that contain one or more unpaired electrons and, thereby, have a strong tendency to take or give electrons to other molecules, which can lead to the change of molecule structure and their decomposition.

The imbalance between antioxidants and oxidants in favour of oxidants is defined as oxidative stress.

Oxidative stress is considered to be widely responsible for large lesions in the aging process, as well as for serious pathological conditions such as:

• neurodegenerative diseases
• malignant neoplasms
• diabetes mellitus
• cardiovascular diseases

Antioxidants are molecules that can donate an electron to a free radical without becoming unstable themselves. That causes free radicals to become more stable and, therefore, less reactive.

EpiNeuron®

is a specially designed formulation of active ingredients whose strong synergistic action qualifies it for the treatment of different pathological conditions involving neuroinflammation, neurodegeneration, and neuropathic pain:

• Stroke and CNS traumas
• Neurodegenerative diseases of the CNS:
  • Parkinson’s disease
  • Alzheimer’s disease
  • Multiple sclerosis
  • Amyotrophic lateral sclerosis (ALS)
• Neuralgia
• Viral infections of the nervous system (Herpes Zoster, HIV)
• Neuropathic pain induced by cancer and chemotherapy
• Phantom pain

EpiNeuron® use with oncology patients

PEA – mechanism of action

• inhibits the production of proinflammatory cytokines that contribute to tumorigenesis
• reduces chemical and radiation resistance of cancer cells
• reduces dose-dependent side effects of different cytostatics which,
• in critical situations, provides a possibility for the administration of a higher dose and longer treatment

SOD + ALA with the addition of vitamin E – mechanism of action

• complete antioxidant block (primary + secondary antioxidants)
• inhibits lipid peroxidation and the formation of free radicals – a process that is one of the mechanisms of malignant neoplasms creation

Owing to the strong synergistic action of the combination of active ingredients, EpiNeuron® can be used in the treatment of different pathological conditions that lead to the generation of pain:

EpiNeuron® is unique due to advance methods in the technology of its production:

• Palmitoylethanolamide – PEA 300 mg
• Superoxide dismutase 70 IU (SOD-GlySODin® – gastro-resistant form of SOD)
• Alpha-lipoic acid 300 mg (Physio Release Technology ®)*
• Vitamin E 7,5 mg
• Vitamin B1 – 1,1 mg
• Vitamin B3 – 9 mg;
• Vitamin B6 – 1,5 mg
• Vitamin B12 – 2,5 mcg
• Magnesium – 30 mg
• Zinc – 2,5 mg

*Physio Release Tehnology ® – a prolonged-release form that guarantees a constant effective level of the active substance in the blood during the treatment.

Dosage and administration

• Dosage: 1-2 times per day after a light meal
• Duration of administration: 3-6 months
• EpiNeuron® is not an opioid and is not addictive
• Does not develop pharmacological tolerance
• Safe
• No interaction with other medicines
• Patients with decreased kidney and liver function can take EpiNeuron®, because its metabolism is independent of the liver and renal function